Application/Control Number: 10/039,770

Art Unit: 1631

CLAIMPTO

WNP

01/05/2005

- 1. (Currently amended) An isolated TgAMA-1 polypeptide molecule comprising consisting essentially of an antigenic fragment of the polypeptide sequence set forth as amino acids 23-456 of SEQ ID NO:1.
- 2. (Original) A fusion protein comprising the antigenic polypeptide of claim 1.
- 14. (Currently Amended) A vaccine composition comprising the isolated TgAMA-1 polypeptide of claim 1 and an adjuvant.
- 38. (Previously Presented) The vaccine composition of claim 14, wherein the vaccine composition is a proteosome vaccine.

CLAIM 40 IN EXAMINERS AMENDMENT

- 23. (Original) A TgAMA-1 binding polypeptide that selectively binds to the isolated TgAMA-1 polypeptide of claim 1.
- 24. (Original) The TgAMA-1 binding polypeptide of claim 23, wherein the binding polypeptide is an antibody or antigen-binding fragment of an antibody.

Application/Control Number: 10/039,770

Art Unit: 1631

Page 3

25. (Original) The TgAMA-1 binding polypeptide of claim 24, wherein the antibody or antigen-binding fragment specifically binds to a region comprising about 12 or more cysteine residues of the isolated polypeptide of claim 1.

26. (Original) The TgAMA-1 binding polypeptide of claim 23, wherein the binding polypeptide blocks entry of Toxoplasma parasite into a cell.